Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290570 | 0.78 | LPL (0.38) | MAPK1LPLLIPGP2RX7 | |
| SCHEMBL20861758 | 0.75 | ERN1 (0.35) | ERN1MAPK1P2RX7 | |
| SCHEMBL20861592 | 0.72 | ERN1 (0.40) | ERN1MAPK1P2RX7 | |
| SCHEMBL17397880 | 0.72 | ERN1 (0.40) | ERN1MAPK1P2RX7 | |
| SCHEMBL17397866 | 0.71 | LMNA (0.37) | ERN1MAPK1P2RX7 | |
| SCHEMBL1803570 | 0.69 | LPL (0.41) | MAPK1LPLLIPG | |
| SCHEMBL31035289 | 0.68 | ERN1 (0.42) | ERN1LPLLIPG | |
| SCHEMBL31088716 | 0.68 | LPL (0.39) | LPLLIPG | |
| SCHEMBL20527113 | 0.68 | MAOB (0.51) | — | |
| SCHEMBL2279721 | 0.67 | CA1 (0.43) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | ERN1 1139/4885MAPK1 988/4885LPL 4845/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | ERN1 1139/4885MAPK1 988/4885LPL 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.